Again, it's not an argument. It's a concern regarding trial design.
And no one here is able to address it.
Should be simple.
The statement was that the FDA advised on the control group. The reasoning was that that is what they do.
The FDA, in fact, says that isn't what they do by default.
So now it should be easy to find, as this is something that some posters were very certain of. But I can't find it.
If you guys don't really care how the trials are designed, or the details of the actual science, that's fine.
You're constantly surprised that MSB isn't succeeding, and yet aren't interested in asking why? Or what could they do differently?
Bizarre! Can't even lead these horses to water, let alone getting them to drink....
Ann: 36-Month Results of Phase 3 Trial in Chronic Low Back Pain, page-108
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |